Early Intervention Program for Autism Spectrum Disorder
Trial Summary
What is the purpose of this trial?
This trial is testing a program where children spend time each week in a special preschool or at home doing activities. The goal is to help children with developmental disorders, like Autism, improve their social communication skills. By engaging in these structured activities, the children can learn to communicate and interact better.
Do I need to stop my current medications to join the trial?
The trial protocol does not specify whether you need to stop taking your current medications.
What data supports the idea that Early Intervention Program for Autism Spectrum Disorder is an effective treatment?
The available research shows that Early Intervention Programs for Autism Spectrum Disorder can lead to significant improvements in various developmental areas for children with autism. For example, one study found that children who participated in early intensive behavioral intervention (EIBI) showed significant gains in intellectual functioning and a decrease in autism symptom severity after treatment. However, these gains in symptom severity were not maintained a year after the treatment ended. Another study highlighted that community-based early intervention programs generally result in medium-to-large improvements compared to usual treatments. While some studies suggest that the benefits of these programs may diminish over time, they still indicate that early intervention can be more effective than standard treatments in the short term. Additionally, the Frankfurt Early Intervention Program (FFIP) showed improvements in socialization and mental age, although these gains were smaller compared to more intensive programs. Overall, the research supports the effectiveness of early intervention programs, especially when compared to typical treatments, but also suggests the need for ongoing support to maintain these benefits.12345
What safety data exists for early intervention programs for autism?
The research indicates that early intensive behavioral interventions (EIBI) and models like the Early Start Denver Model (ESDM) are effective and feasible for young children with autism spectrum disorder (ASD). These interventions have shown positive outcomes in community settings, with high parent satisfaction and good treatment fidelity. However, specific safety data is not detailed in the provided studies, suggesting a need for further research to document safety and effectiveness comprehensively.56789
Is the Center Based Early Intervention Program a promising treatment for autism spectrum disorder?
Yes, the Center Based Early Intervention Program is a promising treatment for autism spectrum disorder. Research shows that early intervention programs, like the Early Start Denver Model and Early Intensive Behavioral Intervention, lead to significant improvements in communication, social skills, and behavior for children with autism. These programs are well-supported by parents and therapists, and they are effective in community settings.2581011
Research Team
Antonio Hardan, MD
Principal Investigator
Stanford University
Eligibility Criteria
This trial is for preschool-aged children (2 to almost 5 years old) diagnosed with developmental disorders like Autism Spectrum Disorder, neurogenetic disorders, or intellectual disability. They must be able to complete certain tests and have no severe psychiatric conditions like bipolar disorder.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a 12-week early intervention program in an intensive center-based preschool environment or in the home
Follow-up
Participants are monitored for changes in social communication deficits after treatment
Treatment Details
Interventions
- Center Based Early Intervention Program (Behavioural Intervention)
- Center Based or In Home Early Intervention Program (Behavioural Intervention)
Center Based Early Intervention Program is already approved in Canada for the following indications:
- Developmental delays
- Autism Spectrum Disorder
- Neurogenetic disorders
Find a Clinic Near You
Who Is Running the Clinical Trial?
Stanford University
Lead Sponsor
Dr. Richard A. Miller
Stanford University
Chief Executive Officer since 2023
Stanford University, MD
Dr. Robert Schott
Stanford University
Chief Medical Officer since 2021
University of Michigan, MD
John & Marcia Goldman Foundation
Collaborator